After TURBT, Anlotinib Hydrochloride combined with radiotherapy to preserve bladder for treatment of myometrial invasive bladder cancer

iuzhou Chinese Medicine Hospital0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1, between the ages of 18 and 85, male or female;
•2. Clearly diagnosed as myometrial invasive bladder cancer by histopathology and/or cytology;
•3. Rejection of chemotherapy after surgery;
•4, with measurable lesions (spiral CT scan greater than 10mm, meet the RECIST1.1 standard);
•5. The patient has an estimated KPS score of 70 or more;
•6. The estimated survival period >=3 months.

•1. End-stage patients cannot tolerate treatment;
•2. The assessment of chronic combined basic diseases may interfere with treatment;
•3. Combined with severe liver and kidney dysfunction;
•4. The tumor has invaded an important blood vessel or a patient who has been judged by the investigator to have major bleeding during the follow-up study;
•5. Patients with any signs or history of bleeding physique.

发起方

iuzhou Chinese Medicine Hospital